Ranjan Perera, Ph.D.

Ranjan Perera

Ranjan Perera, Ph.D.

Scientific Director, Analytical Genomics and Bioinformatics
Associate Professor

Ranjan Perera's Research Focus

Related Diseases > Skin Cancer and Melanoma, Prostate Cancer

Prostate cancer and metastatic melanoma are both difficult cancers to detect early, and once detected late they are nearly always impossible to cure, causing mortality within three years despite surgery and conventional therapies. To find effective treatment it is imperative to understand the biology of these aggressive cancers. Our recent research has provided a novel direction in the biology of these cancers – that abnormal patterns of regulation of certain non-coding RNA (ncRNA) and microRNA genes determine aggressiveness of these cancers. Our genome-wide studies have found evidence for abnormal epigenetic processes, rather than direct gene mutations, that lead to such abnormal ncRNA/miRNA regulation. These findings support an unorthodox approach to investigating such cancers in that epigenetic rather than mutational processes might be the important underlying molecular mechanism behind these aggressive cancers. Therefore, novel therapeutic approaches might be in order. However, much more remains to be understood in this direction. Specifically, the genome-wide systems biology approaches to dissect the epigenetic processes that become abnormal when aggressive prostate cancer and melanoma initiates, rather than the reductionist "gene-by-gene" classical approaches, are urgently necessary. We have embarked upon a systems biology initiative to investigate the role of epigenetic regulation of ncRNA/miRNA expression in these cancers, and now propose to extend this initiative from the laboratory ultimately to the bedside of patients. 

Ranjan Perera's Bio

Ranjan Perera, Ph.D., most recently held faculty positions at Mercer University’s School of Medicine as an Associate Professor and Director of Genomics and R&D at Anderson Cancer Institute at Memorial Health Medical Center. Prior to his academic affiliations, he held positions at several major biotech and pharmaceutical companies, including ISIS Pharmaceuticals and Invitrogen Corporation. He received his Ph.D. in molecular genetics from Moscow State University, Russia and University of Gent, Belgium. He completed his postdoctoral studies in gene targeting and DNA recombination at Massachusetts Institute of Technology (MIT).

IM Program


Zhao W, Mazar J, Lee B, Sawada J, Li JL, Shelley J, Govindarajan S, Towler D, Mattick JS, Komatsu M, Dinger ME, Perera RJ
J Invest Dermatol 2016 Apr;136(4):819-28
Mazar J, Qi F, Lee B, Marchica J, Govindarajan S, Shelley J, Li JL, Ray A, Perera RJ
Mol Cell Biol 2016 Jan 19;36(7):1090-108
Khaitan D, Dinger ME, Mazar J, Crawford J, Smith MA, Mattick JS, Perera RJ
Cancer Res 2011 Jun 1;71(11):3852-62